Voyager Therapeutics Inc. has a Parkinson’s disease gene therapy that could last “essentially for as long as the patient lives, but at least 15 or 20 years,” CEO Steven Paul told BioWorld Today, commenting on phase Ib results with VY-AADC01.

LONDON – A new frontier has opened up in the search for Alzheimer's therapies, with researchers at Massachusetts Institute of Technology reporting they can reduce beta amyloid plaques in mouse models using lights flickering at specific frequencies to stimulate neural circuits.

SAN DIEGO – Imbruvica, the BTK inhibitor that has racked up FDA approvals in B-cell cancers has impressed in a non-oncology indication chronic graft-vs.-host disease with phase II data showing an overall response rate of 67 percent.

SAN DIEGO  Fixing genetic diseases such as hemophilia, sickle-cell disease, and certain immunodeficiencies at their root, by replacing or repairing the faulty gene, has gone from dream to drug, with two gene therapies now approved in Europe, and a number of additional approvals expected on both sides of the Atlantic over the next few years.

With just one month to go before biopharma draws the curtains on a year that has seen its fair share of lows for the sector, it received an early Christmas present following Donald Trump's unexpected victory in the presidential election. Share values of drug developers have soared in the wake of the result because it came with the removal, at least for now, of fears that drug-pricing policy issues will be high on the political agenda going forward.